Results 61 to 70 of about 20,701 (223)

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, EarlyView.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source

Zebrafish Sensitivity to Botulinum Neurotoxins [PDF]

Toxins, 2016
Botulinum neurotoxins (BoNT) are the most potent known toxins. The mouse LD50 assay is the gold standard for testing BoNT potency, but is not sensitive enough to detect the extremely low levels of neurotoxin that may be present in the serum of sensitive animal species that are showing the effects of BoNT toxicity, such as channel catfish affected by ...
Kamalakar Chatla, Patricia Gaunt, Lora Petrie-Hanson, Lorelei Ford, Larry Hanson   +4 more
openaire   +3 more sources

Independent evolution of neurotoxin and flagellar genetic loci in proteolytic Clostridium botulinum

BMC Genomics, 2009
Background Proteolytic Clostridium botulinum is the causative agent of botulism, a severe neuroparalytic illness. Given the severity of botulism, surprisingly little is known of the population structure, biology, phylogeny or evolution of C.
Twine Susan M, Mason David R, Paul Catherine J, Carter Andrew T, Alston Mark J, Logan Susan M, Austin John W, Peck Michael W   +7 more
doaj   +1 more source

Three‐year outcomes of repeated botulinum neurotoxin A injections to the lower extremities in young children with spastic cerebral palsy in GMFCS levels I to III

Developmental Medicine &Child Neurology, EarlyView.
In this study, we followed a group of children 2 to 6 years old with spastic cerebral palsy functioning in GMFCS levels I–III, over 3 years. Sixty‐five received BoNT‐A and 59 did not. Repeated BoNT‐A injections over 3 years were not associated with improvements in gross motor function or passive ankle dorsiflexion. Daily step counts, favouring the BoNT‐
Darcy Fehlings, Emma Bohn, Lauren Switzer, Charles H. Goldsmith, Unni Narayanan, Peter L. Rosenbaum, F. Virginia Wright, Gary Foster, CP‐BoNT‐A Study Group, Timothy Carey, Mark Mason, Ronit Mesterman   +11 more
wiley   +1 more source

Histopathological changes of the buccal mucosa and skin after botulinum neurotoxin intramuscular injection in rats (immunohistochemical study)

BMC Oral Health
Background A surplus of clinical studies focused mainly on the clinical impacts of botulinum neurotoxin type A disregarding the histopathological changes stemming from its injection.
Gihan S. Hassan, Basant H. Abouzaid, Reda G. Saleh   +2 more
doaj   +1 more source

Botulinum neurotoxin: Not only in Dermatology - Expanding Therapeutic Horizons Across Medical Specialties

Journal of Education, Health and Sport
Background. Botulinum neurotoxin (BTX) is commonly associated with cosmetic applications; however, its therapeutic relevance extends far beyond aesthetic medicine.
Klaudia Kurzątkowska, Dominika Marszałek, Aleksandra Ocimek, Michalina Czudowska, Magdalena Zawadzka, Emilia Borychowska, Karolina Gwóźdź, Zofia Aneta Mierzejewska, Marta Drozdowska, Aleksandra Natalia Bytros   +9 more
doaj   +1 more source

Single Application of A2 NTX, a Botulinum Toxin A2 Subunit, Prevents Chronic Pain Over Long Periods in Both Diabetic and Spinal Cord Injury–Induced Neuropathic Pain Models

Journal of Pharmacological Sciences, 2012
Botulinum toxin type A is a unique candidate for inhibition of pain transmission. In the present study we attempted to see the beneficial actions of A2 neurotoxin (NTX), an active subunit of botulinum toxin type A.
Lin Ma, Jun Nagai, Yuki Sekino, Yoshitaka Goto, Shinji Nakahira, Hiroshi Ueda   +5 more
doaj   +1 more source

Embryonic Stem Cell-Derived Neurons Grown on Multi-Electrode Arrays as a Novel In vitro Bioassay for the Detection of Clostridium botulinum Neurotoxins [PDF]

, 2017
Clostridium botulinum neurotoxins (BoNTs) are the most poisonous naturally occurring protein toxins known to mankind and are the causative agents of the severe and potentially life-threatening disease botulism.
Anne Tscherter, Denis Grandgirard, Marc-André Avondet, Martina Heidemann, Stephen L. Leib, Stephen P. Jenkinson   +5 more
core   +1 more source

Passive shoulder mobility and active shoulder external rotation recovery in upper‐trunk brachial plexus birth injuries after nerve repair

Developmental Medicine &Child Neurology, EarlyView.
This was a retrospective cohort study of 322 patients with upper trunk brachial plexus birth injury following nerve surgery of C5 and/or C6. We found that a substantial gap remained between passive and active shoulder external rotation in adduction, indicating that passive mobility is not the limiting factor in active external rotation recovery ...
Eva T. E. Ulmann, Jochem Nagels, Willem Pondaag, Martijn J. A. Malessy   +3 more
wiley   +1 more source

Genomic and physiological variability within Group II (non-proteolytic) Clostridium botulinum [PDF]

, 2013
BACKGROUND: Clostridium botulinum is a group of four physiologically and phylogenetically distinct bacteria that produce botulinum neurotoxin. While studies have characterised variability between strains of Group I (proteolytic) C. botulinum, the genetic
Andrew T Carter, Ewelina Wachnicka, Lisa C Crossman, Martin D Webb, Michael W Peck, Mohammed Sebaihia, Sandra C Stringer   +6 more
core   +1 more source